A need exists for a simple, less-invasive test to diagnose Alzheimer’s disease and similar neurodegenerative conditions in living people, perhaps even before memory loss becomes obvious.
People spend about a third of their lives asleep. When we get too little shut-eye, it takes a toll on attention, learning and memory, not to mention our physical health. Virtually all animals with complex brains seem to have this same need for sleep. But exactly what is it about sleep that’s so essential?
Howard Feldman of University of British Columbia is known for seminal research in dementias; UC launches new $4 million Alzheimer’s disease initiative.
One of the longest and most anticipated Alzheimer drug studies in history is about to begin, and Dr. Reisa Sperling is wondering if people will come. It’s called the A4 study, and Sperling is the project leader.
Dr Sadowski talks about the potential of the EXERT Study to help identify the right dose of exercise to offset memory loss for people at risk for Alzheimer’s disease
We are thrilled to begin the New Year with over 50,000 participants in Brain Health Registry! We are grateful for your help in achieving this significant milestone, and cannot thank you enough for your efforts to help scientists better understand brain disease.
A team of scientists, including Paul Aisen, MD, professor of neuroscience and director of the Alzheimer’s Disease Cooperative Study, issued a sort of post-mortem on semagacestat, a small-molecule gamma-secretase inhibitor that drug developer Eli Lilly hoped would prove to be an effective treatment for Alzheimer’s disease (AD).
Researchers led by Stephanie Vos and Pieter Jelle Visser at Maastricht University in the Netherlands and Anne Fagan and others at Washington University in St. Louis, Missouri, analyzed data from 311 cognitively normal elderly people seen at St. Louis’s Knight Alzheimer’s Disease Research Center.
Link to the report home page, summary, and PDFs of the full report.
What’s next in the Raskind/Peskind Prazosin research? They are directing the ADCS’ Peace AD trial which will test Prazosin, as a treatment for disruptive agitation, in people with moderate to severe Alzheimer’s disease. The trial is launching this spring in over 20 memory and long term care communities in the US.
No use soft-pedaling a hard truth: The year ended on a downer. Solanezumab—the therapeutic antibody in line to be the first approved AD drug in well over a decade—failed to significantly slow cognitive decline in people with mild AD and a positive amyloid scan/CSF Aβ profile.
In lieu of a crystal ball that can foresee Alzheimer’s, scientists are trying to divine impending disease by looking deep into a person’s genome.
These concepts were approved at the National Advisory Council on Aging (NACA) meeting on January 18, 2017. We have posted the approved concepts here to give interested researchers maximal lead time to plan projects.
A protein called Aβ is thought to cause neuronal death in Alzheimer’s disease (AD). Aβ forms insoluble aggregates in the brains of patients with AD, which are a hallmark of the disease. Aβ and its propensity for aggregation are widely viewed as intrinsically abnormal. However, in new work, Kumar et al. show that Aβ is…
Remarkably, this boost in cognition occurred despite the accumulation of Alzheimer-related toxins in the brain, such as amyloid-beta and tau.
A family with an astonishing rate of Alzheimer’s disease may harbor a powerful new gene.
The AlzForum’s editorial team provides a comprehensive recap of the last year in Alzheimer’s research and related public policy developments.
Read the exceptional compilation of AD-related data and statistics. Includes a Special Report on the Next Frontier of Alzheimer’s Research
“Namzaric combines, in one capsule, two complementary therapeutic agents which are often co-prescribed as approximately 70% of Namenda XR patients are also on AChEI therapy. Both Namenda XR and donepezil have proven efficacy and safety, for the treatment of moderate/severe Alzheimer’s disease.”
We now have more accurate ways of diagnosing Alzheimer’s and are moving closer to developing drugs to directly attack the disease. Much of this work is still in the early stages, but experts are growing more hopeful about dealing with the debilitating disease, which currently has no cure.